The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β‐glucosidase
Open accessAbstract
Gaucher disease is caused by mutations in the gene that encodes the lysosomal enzyme acid β‐glucosidase (GCase). We have shown previously that the small molecule pharmacological chaperone isofagomine (IFG) binds and stabilizes N370S GCase, resulting in increased lysosomal trafficking and cellular activity. In this study, we investigated the effect of IFG on L444P GCase. Incubation of Gaucher patient‐derived lymphoblastoid cell lines (LCLs) or fibroblasts with IFG led to approximately 3.5‐ and 1.3‐fold increases in L444P GCase activity, respectively, as measured in cell lysates. The effect in fibroblasts was increased approximately 2‐fold using glycoprotein‐enrichment, GCase‐immunocapture, or by incubating cells overnight in IFG‐free media prior to assay, methods designed to maximize GCase activity by reducing IFG carryover and inhibition in the enzymatic assay. IFG incubation also increased the lysosomal trafficking and in situ activity of L444P GCase in intact cells, as measured by reduction in endogenous glucosylceramide levels. Importantly, this reduction was seen only following three‐day incubation in IFG‐free media, underscoring the importance of IFG removal to restore lysosomal GCase activity. In mice expressing murine L444P GCase, oral administration of IFG resulted in significant increases (2‐ to 5‐fold) in GCase activity in disease‐relevant tissues, including brain. Additionally, eight‐week IFG administration significantly lowered plasma chitin III and IgG levels, and 24‐week administration significantly reduced spleen and liver weights. Taken together, these data suggest that IFG can increase the lysosomal activity of L444P GCase in cells and tissues. Moreover, IFG is orally available and distributes into multiple tissues, including brain, and may thus merit therapeutic evaluation for patients with neuronopathic and non‐neuronopathic Gaucher disease. Structured digital abstract MINT‐7555323, MINT‐7555338, MINT‐7555398: LAMP1 (uniprotkb: P11279) and GCase (uniprotkb:P04062) colocalize (MI:0403) by fluorescence microscopy (MI:0416)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
Hollak, C. E., van Weely, S., van Oers, M. H., & Aerts, J. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117084 · Cited by 896
Benjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R. J., et al. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-1077-0 · Cited by 173
Self-citation
Cited by
The Role of Autophagy in Parkinson's Disease
Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M., & Klionsky, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009357 · Cited by 458
Glucocerebrosidase and its relevance to Parkinson disease
Do, J., McKinney, C., Sharma, P., & Sidransky, E. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0336-2 · Cited by 300
Desnick, R. J., & Schuchman, E. H. (2012) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090711-163739 · Cited by 269
GBA Variants and Parkinson Disease: Mechanisms and Treatments
Smith, L., & Schapira, A. H. V. (2022) · Cells · doi:10.3390/cells11081261 · Cited by 256
Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease
Panicker, L. M., Miller, D., Park, T. S., Patel, B., Azevedo, J. L., Awad, O., Masood, M. A., Veenstra, T. D., Goldin, E., Stubblefield, B. K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207889109 · Cited by 129
Metadata
- Authors
- Khanna, R., Benjamin, E. R., Pellegrino, L., Schilling, A., Rigat, B. A., Soska, R., Nafar, H., Ranes, B. E., Feng, J., Lun, Y., Powe, A. C., Palling, D. J., Wustman, B. A., Schiffmann, R., Mahuran, D. J., Lockhart, D. J., & Valenzano, K. J.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2010-03-15
- Volume
- 277
- Issue
- 7
- Pages
- 1618-1638
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W1533651529
- Cited by
- 161
- References
- 2
- FWCI
- 10.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β‐glucosidase. https://app.cochat.ai/papers/10.1111/j.1742-4658.2010.07588.x
- The paper
- Khanna, R., Benjamin, E. R., Pellegrino, L., Schilling, A., Rigat, B. A., Soska, R., Nafar, H., Ranes, B. E., Feng, J., Lun, Y., Powe, A. C., Palling, D. J., Wustman, B. A., Schiffmann, R., Mahuran, D. J., Lockhart, D. J., & Valenzano, K. J. (2010). The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β‐glucosidase. The FEBS Journal. https://doi.org/10.1111/j.1742-4658.2010.07588.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.